Propanc Biopharma, Inc.
PPCB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -2.46% | -846.06% | -136.45% | -6,469,837.84% |
| EV / EBITDA | -0.31 | -0.82 | -0.60 | -0.48 |
| Quality | ||||
| ROIC | -366.39% | 50.67% | 65.89% | 98.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | 0.51 | 0.42 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 56.67% | 15.39% | 23.05% | -25.41% |
| Safety | ||||
| Net Debt / EBITDA | -0.03 | -0.73 | -0.24 | -0.48 |
| Interest Coverage | -101.60 | -2.31 | -3.34 | -3.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -20,450.10 | -19,867.80 | 0.00 |